# Jazz Pharmaceuticals, Inc. (JAZZ) — Stock CV

Jazz Pharmaceuticals, Inc. is a $14.2B healthcare company. Revenue grew 12.6% over the last year, it keeps 20¢ of every dollar of sales as profit, and its net debt equals ~1.8 years of free cash flow. It trades at 15.1× earnings — near the lowest of its own history.

> Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology.

## Identity

- **Ticker**: JAZZ
- **Sector**: Healthcare
- **Industry**: Pharmaceutical Preparations
- **Headquarters**: DUBLIN
- **Employees**: 2 890
- **Website**: https://www.jazzpharmaceuticals.com
- **Market cap**: $14.2B
- **Last price**: $218.42
- **Financial profile**: Mixed

## Vitals (TTM)

- **Revenue**: $4.60B
- **Net income**: $941M
- **Free cash flow**: $1.59B
- **Net debt**: $2.94B
- **P/E**: 15.1
- **Revenue growth (YoY)**: 12.6%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 90 |
| Growth | 37 |
| Profitability | 65 |
| Health | 48 |
| Quality | 77 |
| Moat | 25 |

## Qualifications (beginner checklist) — 9 of 10 passed

- [x] Revenue growing — +12.6% YoY
- [x] Profitable — $941M TTM
- [ ] Profit growing — -163.6% YoY
- [x] Generates cash — $1.59B TTM
- [x] Debt under control — ~1.8y of cash flow to repay
- [x] Established company — $14.2B market cap
- [x] Not printing shares — +7.9% shares over ~5y
- [x] Proven track record — 7/10 profitable years
- [x] Financially stable — Altman Z 2.1 — grey
- [x] Valuation not extreme — P/E 15.1

## Experience (career milestones)

- **FY2024** — Best year on record: $560M net income
- **FY2016** — First recorded profitable year: $397M net income
- **FY2016** — Revenue already above $1B: $1.49B in first reported year
- **FY2016** — Positive free cash flow every year since: 10-year streak
- **2003** — It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland

## Strengths

- High gross margin (88.4%)
- Strongly profitable — 20.4% net margin
- Revenue growing 12.6% year over year
- Strong cash conversion — FCF is 34.6% of revenue
- Could repay net debt from ~1.4 years of free cash flow

## Watch-outs

- Thin interest coverage (-2.2×)
- Loss-making in 3 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $3.09B | -$330M | $751M |
| FY2022 | $3.66B | -$224M | $1.24B |
| FY2023 | $3.83B | $415M | $1.07B |
| FY2024 | $4.07B | $560M | $1.36B |
| FY2025 | $4.27B | -$356M | $1.30B |

---

Source: https://stockcv.com/JAZZ — derived from company filings; may be delayed or incomplete. Information, not investment advice.